Dr Reddy’s Laboratories (DRL) has launched levocetirizine tablets (5mg), a bioequivalent generic version of Xyzal tablets in the US market.  Xyzal is a registered trademark of the UCB Group of companies. The US FDA approved DRL’s ANDA for levocetirizine tablets on February 24, 2011. Levocetirizine had total US sales of approximately $238 million for the twelve months ending September 30, 2010 according to IMS Health. DRL levocetirizine tablets are available in 90 count bottles.

Through DRL's three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – it offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and paediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela,South. Africa, Romania, and New Zealand.